Tiny Cell Vesicles Hold Big Biomarker Potential

The FedEx Packages Inside Your Blood

You have trillions of tiny biological envelopes floating through your veins right now. They carry proteins, fragments of RNA, pieces of DNA, lipids, and metabolites. They are called extracellular vesicles, or EVs, and for most of human history we had no idea they existed. We thought cells communicated through direct contact or by releasing molecules into the open. We were wrong.

Every cell in your body constantly pinches off these microscopic parcels and sends them to other cells. The cargo inside each vesicle is not random. It is a deliberate selection, a message from the originating cell about its current state. A cancerous cell, for instance, packages specific molecules into its vesicles that differ from what a healthy cell would send. This means your blood, urine, saliva, and even your tears contain a real time readout of what is happening inside every organ in your body.

The problem has been that we could not reliably tell the difference between one type of vesicle and another. We could not separate the signal from the noise. We could not agree on what to call them. For a decade, the field has been stuck in a kind of scientific adolescence, full of promise but lacking the maturity to deliver.

That changed in 2024, when the International Society for Extracellular Vesicles published MISEV2023, an updated set of guidelines that essentially functions as the field's constitution (Welsh et al., 2024). More than 1,000 researchers contributed to it. It is not a discovery paper. It is something rarer and more useful: a playbook for how to do the work correctly.

Why Your Cells Are Shipping Packages You Never Knew About

Extracellular vesicles are not a niche curiosity. They are a fundamental mode of cellular communication that we have only recently learned to see. Every cell type produces them. They range in size from about 30 nanometers to several micrometers. That is smaller than a virus at the small end, and about the size of a bacterium at the large end.

The authors of MISEV2023 describe EVs as particles that are "released from a cell, are delimited by a lipid bilayer, and cannot replicate" (Welsh et al., 2024). That last part matters. Because they cannot replicate, they are not alive. They are cargo containers. But they contain the fingerprints of the cells that made them.

When a cancer cell releases an EV, that vesicle carries certain proteins and RNAs that are characteristic of that specific cancer type. When a neuron is stressed, its EVs contain different molecules than when it is healthy. When a heart muscle is damaged, the vesicles in your blood change composition within hours.

This is why the field has exploded. The number of scientific publications about EVs has increased steadily year after year, according to the authors (Welsh et al., 2024). Everyone wants a piece of this. Pharmaceutical companies want to use EVs as delivery vehicles for drugs. Diagnostic companies want to use them as liquid biopsies to detect cancer early. Basic scientists want to understand how cells actually talk to each other.

But there was a problem. Everyone was doing it differently.

The Tower of Babel Problem in Vesicle Research

Before MISEV2023, the field had a nomenclature crisis. Some researchers called everything an "exosome." Others used "microvesicle." Still others used "shedding vesicle" or "microparticle." The problem was that these terms implied specific biogenesis pathways that researchers could not actually prove with the methods they were using.

The authors of MISEV2023 acknowledge this directly. They write that "hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies" (Welsh et al., 2024).

Translation: We did not know what we were looking at, we could not agree on what to call it, and we could not separate the real vesicles from the junk floating around in our samples.

The guidelines address this by recommending that researchers stop using terms like "exosome" unless they can provide rigorous evidence of the specific intracellular origin of those vesicles. Instead, the authors suggest operational terms based on size, density, or biochemical composition. Call them "small EVs" or "large EVs" until you can prove otherwise.

This is not pedantry. This is the difference between a field that produces reproducible results and one that produces noise.

How to Catch a Vesicle Without Breaking It

The technical challenges of EV research are formidable. Imagine trying to separate a specific type of envelope from a pile of mail, except the envelopes are smaller than the wavelength of visible light, they float in a complex biological fluid, and you cannot see them while you are sorting.

The authors of MISEV2023 describe multiple approaches for EV separation, each with tradeoffs. Ultracentrifugation spins samples at extremely high speeds to pellet the vesicles. It is the most common method, but it also pellets non-vesicular particles and can damage the vesicles themselves. Size exclusion chromatography separates particles by size using a column packed with porous beads. It is gentler but less pure. Immunoaffinity capture uses antibodies to bind specific surface proteins on EVs. It is specific but requires knowing which proteins to target.

There is no perfect method. The authors emphasize that researchers should use complementary approaches and report their methods in enough detail that others can reproduce them (Welsh et al., 2024).

The same principle applies to characterization. The guidelines recommend measuring at least three parameters for any EV preparation: the number of particles, the amount of protein or lipid, and the presence of EV associated markers. Without all three, you cannot be sure you are actually studying vesicles and not some other contaminant.

This might sound like basic scientific hygiene. But before MISEV2023, many papers did not meet even this minimal standard. The guidelines are trying to raise the floor.

What We Actually Know About What Vesicles Do

The cargo inside EVs is not random debris. The authors of MISEV2023 describe how EVs "through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells" (Welsh et al., 2024).

This is the core claim that makes EVs so exciting. They are both diagnostic and functional. They tell you what is happening in the cell that made them, and they can alter the behavior of the cells that receive them.

Consider what this means for cancer detection. A tumor growing in your pancreas sheds EVs into your bloodstream. Those vesicles carry mutant DNA, specific microRNAs, and proteins that are characteristic of pancreatic cancer. A simple blood draw could theoretically detect these vesicles long before a tumor is visible on a scan.

Consider what this means for therapy. You could engineer a patient's own cells to produce EVs that carry a therapeutic payload. Those vesicles could deliver drugs directly to diseased cells, potentially avoiding the side effects of systemic administration.

Consider what this means for basic biology. We used to think the brain was an immune privileged organ, isolated from the rest of the body. But EVs cross the blood brain barrier. They carry signals from the brain to the periphery and back. The authors of MISEV2023 include a new section on in vivo approaches to study EVs, reflecting how much this understanding has changed (Welsh et al., 2024).

The New Rules for Studying Vesicle Release and Uptake

MISEV2023 includes entirely new sections on EV release and uptake that were absent from the 2018 version. This is a sign of how rapidly the field is maturing.

The authors describe how cells release EVs through multiple mechanisms. Some bud directly from the plasma membrane. Others form inside the cell in structures called multivesicular bodies and are released when those bodies fuse with the plasma membrane. The molecular machinery involved includes proteins like ESCRT, Rab GTPases, and lipids like ceramide.

But here is the catch. The authors note that "the molecular mechanisms of EV release are incompletely understood" (Welsh et al., 2024). We know some of the players, but we do not have the full playbook.

The same is true for uptake. Once an EV reaches a target cell, how does it get inside? Does it fuse with the plasma membrane? Does it get endocytosed? Does it bind to specific receptors? The answer is probably "all of the above," depending on the cell type and the vesicle type.

The guidelines do not pretend to have solved these questions. Instead, they provide a framework for asking them rigorously. They recommend that researchers use multiple inhibitors and genetic tools to confirm mechanisms, rather than relying on a single approach.

The Big Question the Field Has Not Answered

Here is what MISEV2023 does not tell us, and it is worth being honest about this.

The guidelines tell us how to study EVs. They do not tell us which EV populations matter most for biology or medicine. That is still an open question.

Consider the heterogeneity problem. A single cell can release multiple types of EVs with different sizes, different cargo, and different functions. Are all of these biologically relevant, or are some just cellular trash disposal? The authors acknowledge that "non vesicular extracellular particles" exist and can contaminate EV preparations (Welsh et al., 2024). But they do not claim to know which particles are signal and which are noise.

Consider the specificity problem. Many of the molecules found in EVs are also found in other parts of the blood. If you detect a cancer associated protein in a plasma sample, how do you know it came from a vesicle and not from a dead cell or a circulating protein complex? The guidelines provide methods for addressing this, but they do not eliminate the uncertainty.

Consider the functional relevance problem. Just because a vesicle contains a particular molecule does not mean that molecule does anything when the vesicle reaches a target cell. The authors emphasize the need for functional studies, but those studies are still rare and technically challenging.

These are not criticisms of the guidelines. They are honest statements about where the field stands. MISEV2023 is a map of known knowns and known unknowns. The unknown unknowns are still out there.

What This Actually Means

• ▸If you are a researcher studying EVs, the most important thing you can do is follow the MISEV2023 checklist. Report your separation method in detail. Measure at least three parameters to characterize your preparation. Do not call something an exosome unless you can prove its intracellular origin. The guidelines are not bureaucratic overhead. They are the difference between publishable results and reproducible ones.

• ▸If you are a clinician hoping to use EVs for liquid biopsy, be skeptical of claims based on single marker detection. The authors recommend using multiple markers to confirm vesicle identity. A single protein or RNA in the blood could come from many sources. The power of EVs lies in their cargo complexity, not in any single molecule.

• ▸If you are a patient reading about EV based diagnostics or therapies, understand that the field is still in its early stages. The guidelines were developed precisely because the field was not ready for clinical translation. That does not mean it will never be ready. It means we are still building the foundation.

• ▸If you are a funder or a journal editor, enforce the MISEV2023 standards. The authors compiled feedback from more than 1,000 researchers to create these guidelines. They represent the consensus of the field. Papers that do not meet these standards should not be published. Studies that do not follow these protocols should not be funded.

• ▸If you are a curious person who wants to understand how cells actually communicate, this is one of the most interesting stories in modern biology. Your cells are constantly sending packages to each other. We are only beginning to learn how to read the labels. The MISEV2023 guidelines are the instruction manual for that work. They are not glamorous. But they are necessary. And they might be the thing that finally turns a promising field into a productive one.